Biotech Values

[DewDiligence]

MRK—I expect some younger, healthier patients will opt for Keytruda + chemo in first-line NSCLC even if they technically qualify for Keytruda monotherapy. No reason for third-party payers to oppose this insofar as the chemo drugs in question are cheap generics.